Aurinia
Aurinia Pharmaceuticals, a clinical-stage nephrology firm, has appointed Kurt von Emster, a founding partner of venBio, to its Board of Directors, effective immediately.
The company said the appointment was connected to its $52m (€38m) private placement, which it intends to use “to advance the clinical and nonclinical development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis and for general corporate purposes.”
The financing was led by venBio, New Enterprise Associates (NEA), Redmile Group, RA Capital Management, Great Point Partners, and Apple Tree Partners, among other life science investors and existing shareholders.